News
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...
6h
Zacks Investment Research on MSNHere's Why Gilead Sciences (GILD) Fell More Than Broader MarketIn the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...
Pennsylvania will receive $1.28 million as part of a $202 million national settlement with Gilead Sciences Inc., after the company was accused of orchestrating an illegal ...
Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...
Pennsylvania looks to be getting millions from a biopharma company for violating anti-kickback laws. Gilead Sciences, Inc.
A company was ordered to pay hundreds of thousands of dollars to D.C. to settle claims that it engaged in an illegal kickback scheme.
Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results